Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AJMC reported the partners would jointly develop and commercialize Opdivo, Yervoy, and three early-stage immunotherapies (lirilumab, urelumab,…
"Our collaboration with Bristol-Myers Squibb strengthens our ability to further enhance the potential of Opdivo, for which ONO recently received manufacturing…
Ten years post-deal, Ono and BMS continued joint label expansion—filing supplemental Opdivo+Yervoy applications in Japan for MSI-high colorectal…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
BMS and Ono expanded their long-running PD-1 collaboration to jointly develop and commercialize Opdivo, Yervoy and three early immunotherapies in Japan, South Korea and Taiwan—markets where Ono historically retained rights. Strategically pivotal as Opdivo received the world's first PD-1 approval in Japan that same month.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. (this deal) | 2014 | — | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2014 deals · Bristol-Myers Squibb Company deals · Oncology deals